Literature DB >> 12745064

Molecular characterisation of six alternatively spliced variants and a novel promoter in human peroxisome proliferator-activated receptor alpha.

Choy Hoong Chew1, Mohd Razip Samian, Nazalan Najimudin, Tengku Sifzizul Tengku-Muhammad.   

Abstract

Peroxisome proliferator-activated receptor alpha (PPARalpha) is a ligand-activated transcriptional factor that governs many biological processes, including lipid metabolism, inflammation, and atherosclerosis. We demonstrate here the existence of six variants and multiple transcriptional start sites of the 5(') untranslated region (UTR) of hPPARalpha gene, originating from the use of alternative splicing mechanisms and four different promoters. Three new novel exons at the 5(')-untranslated region of human PPARalpha gene were also identified and designated as Exon A, Exon B, and Exon 2b. In addition, 1.2kb promoter fragment which drives the transcription of 2 variants with Exon B (hPPARalpha4 and 6) was successfully cloned and characterised. Sequencing results revealed promoter B did not contain a conservative TATA box within the first 100 nucleotides from transcriptional start site but has several GC-rich regions and putative Sp1 sites. Using luciferase reporter constructs transfected into HepG2 and Hep3B cell lines, promoter B was shown to be functionally active. Basal transcriptional activity was significantly high in the promoter fragment -341/+34, but lower in the region -341/-1147 as compared to the fragment -341/+34, indicating the presence of an element conferring transcriptional activation between positions -341 and +34 or alternatively, the presence of transcriptional repression between positions -341 and -1147 in the promoter B of hPPARalpha.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12745064     DOI: 10.1016/s0006-291x(03)00731-9

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  8 in total

1.  ChREBP mediates glucose repression of peroxisome proliferator-activated receptor alpha expression in pancreatic beta-cells.

Authors:  Michael Boergesen; Lars la Cour Poulsen; Søren Fisker Schmidt; Francesca Frigerio; Pierre Maechler; Susanne Mandrup
Journal:  J Biol Chem       Date:  2011-01-31       Impact factor: 5.157

2.  Rare PPARA variants and extreme response to fenofibrate in the Genetics of Lipid-Lowering Drugs and Diet Network Study.

Authors:  Marguerite R Irvin; Qunyuan Zhang; Edmond K Kabagambe; Rodney T Perry; Robert J Straka; Hemant K Tiwari; Ingrid B Borecki; Lawrence C Shimmin; Colin Stuart; Yu Zhong; James E Hixson; Donna K Arnett
Journal:  Pharmacogenet Genomics       Date:  2012-05       Impact factor: 2.089

3.  Association and interaction of PPAR-complex gene variants with latent traits of left ventricular diastolic function.

Authors:  Jyh-Ming Jimmy Juang; Lisa de Las Fuentes; Alan D Waggoner; C Charles Gu; Víctor G Dávila-Román
Journal:  BMC Med Genet       Date:  2010-04-28       Impact factor: 2.103

4.  Expression of peroxisome proliferator-activated receptor-gamma in the substantia nigra of hemiparkinsonian nonhuman primates.

Authors:  Christine Swanson; Marina Emborg
Journal:  Neurol Res       Date:  2013-12-27       Impact factor: 2.448

5.  Interleukin-6 inhibition of peroxisome proliferator-activated receptor alpha expression is mediated by JAK2- and PI3K-induced STAT1/3 in HepG2 hepatocyte cells.

Authors:  Guat-Siew Chew; Stephen Myers; Alexander Chong Shu-Chien; Tengku Sifzizul Tengku Muhammad
Journal:  Mol Cell Biochem       Date:  2013-11-16       Impact factor: 3.396

6.  Tissue-specific 5' heterogeneity of PPARα transcripts and their differential regulation by leptin.

Authors:  Emma S Garratt; Mark H Vickers; Peter D Gluckman; Mark A Hanson; Graham C Burdge; Karen A Lillycrop
Journal:  PLoS One       Date:  2013-06-25       Impact factor: 3.240

7.  A PPARα promoter variant impairs ERR-dependent transactivation and decreases mortality after acute coronary ischemia in patients with diabetes.

Authors:  Sharon Cresci; Janice M Huss; Amber L Beitelshees; Philip G Jones; Matt R Minton; Gerald W Dorn; Daniel P Kelly; John A Spertus; Howard L McLeod
Journal:  PLoS One       Date:  2010-09-03       Impact factor: 3.240

8.  PPAR Genomics and Pharmacogenomics: Implications for Cardiovascular Disease.

Authors:  Sharon Cresci
Journal:  PPAR Res       Date:  2008       Impact factor: 4.964

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.